and rats [3] . In these studies, no adverse side effects of BBIC were documented for 78 either animal growth or organ physiology. BBI-like proteins from field beans (Dolichos lablab) 79 have been shown to be biologically active in suppressing benzopyrene-induced forestomach 80 carcinogenesis in mice, following oral treatment [13] . The effectiveness of BBI in the reduction 81 and/or suppression of inflammatory processes within the GIT has been reported also. Addition of 82 BBIC to the diet of mice resulted in a suppression of inflammation in the dextran sulphate sodium 83 model of ulcerative colitis [14] and such a beneficial effect could be related to the ability of BBI to 84 inhibit serine proteases, such as leukocyte elastase, cathepsin G and mast cell chymase, released 85 from inflammation-mediating cells. 86
In legume seeds, BBI are proteins with two inhibitory loops that can independently inhibit 87 two enzyme molecules. These may be the same (trypsin-like) or different (trypsin-and 88 chymotrypsin-like) enzymes [15, 16] ; additionally, some BBI can inhibit leukocyte elastase [4] . 89
Because of an apparent association of the chymotrypsin inhibitory binding site with anti-90 carcinogenic properties [17] , it has been hypothesised that chymotrypsin-like proteases are likely 91 to be involved in carcinogenesis [18] . Recently, we have demonstrated the effect of sequence 92 variation within the chymotrypsin inhibitory domain of BBI from pea on their functional properties 93
[19] as well as on their ability to inhibit the growth of human colorectal adenocarcinoma cells [20] . 94 quantitative assay, with BAPNA as specific substrate, and using 50 mM Tris, pH 7.5 as enzyme 126 assay buffer. One trypsin inhibitor unit (TIU) was defined as that which gives a reduction in 127 absorbance at 410 nm of 0.01, relative to trypsin control reactions, in a defined assay volume of 10 128 mL [21] . CIA was measured using BTEE as specific substrate. One chymotrypsin inhibitor unit 129 (CIU) was defined as that which gives a reduction in absorbance at 256 nm of 0.01, relative to 130 chymotrypsin control reactions, in a defined assay volume of 10 mL [19] . Specific TIA and CIA of 131 major soybean BBI isoinhibitors, expressed as inhibitor units (IU) per mg of protein, were 132 calculated. The inhibition constants (K i ) of purified isoinhibitors for trypsin (at pH 7.5) and 133 chymotrypsin (at pH 7.8), were determined from dose-response curves by competitive assays, 134 using the chromogenic substrates BAPNA and BTEE, respectively [19] . The reactions were 135 initiated by adding trypsin (108 nM) or chymotrypsin (28 nM) with the respective substrate 136 concentrations determined by K m measurements. The concentration of inhibitor required to achieve 137 a half-maximal degree of inhibition (IC 50 ) was determined for each protease, using the GraFit 138 software (GraFit Version 5, Erithacus Software Ltd., Horley, UK). K i were calculated from IC 50 139 values using the tight-binding equations for competitive inhibitors as previously described by 140
Copeland et al. [22] . The trypsin and chymotrypsin inhibitory properties of soybean BBI were 141 analyzed furthermore on 4-16 % zymogram blue casein gels (Invitrogen, Barcelona, Spain). 142
Unfractionated BBI or individual isoinhibitors (16 or 32 µg, respectively) were loaded on 143 zymogram gels for the detection of trypsin or chymotrypsin inhibitory activity. Following 144 electrophoresis, and according to the manufacturer´s instructions, gels were treated with zymogram 145 renaturating buffer (Invitrogen) for 30 min at room temperature, equilibrated with zymogram 146 developing buffer (Invitrogen), incubated with 10 mL of trypsin or chymotrypsin solution (0.2 147 mg/mL of zymogram developing buffer) at 37 ºC for 1.5 h, and washed with distilled water before 148 the addition of acetic acid to stop the enzymatic reaction. Areas of the gels that remained blue 149 indicated where trypsin or chymotrypsin had been inhibited. 150 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 min. The flow rate and volume injection were 1 mL/min and 100 µL, respectively, and the 167 absorbance was recorded at 214 nm using a Beckman 166 UV detector. Eluted proteins were 168 collected manually, concentrated in a vacuum centrifuge (SpeedVac Concentrator A 160, Savant 169
Instruments, Farmingdale, NY 11735, USA) and stored at -20 °C, before further analyses. The 170 purity of the BBI isoinhibitors was determined by IEF; 10 µg of each isoinhibitor were dissolved 171 in Novex® IEF pH 3-7 sample buffer and loaded on Novex® gels in the pH range 3-7, according 172 to the manufacturer´s protocol (Invitrogen). Gels were stained using the Colloidal Blue staining kit 173 (Invitrogen). 174 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 ice-cold 70 % ethanol (2 mL) for 30 min at 4 ºC, before addition of 100 µL RNase (1 mg/mL) and 224 100µL of propidium iodide (400 µg/mL). After incubation for 30 min at 37 ºC in the dark, the 225 (Figure 2a) , that were not collected to maximize the purity of the 246 major isoinhibitors. In order to identify the purified isoinhibitors, in-gel tryptic digestion of excised 247 bands was performed, followed by separation of the peptides generated and mass spectrometric-248 based analysis. A search of peptide mass data against the MS protein sequence database (MSDB) 249 enabled the unambiguous identification of both BBI isoinhibitors. The purified proteins, 250 The specific TIA and CIA of the starting material (commercially available BBI, Figure 1 ) 264 were 3075 ± 59 and 2190 ± 27 units per mg of protein, respectively. Following reduction and 265 alkylation of disulphide bonds, these activities were reduced by greater than 95 % (data not shown). 266
Of the two purified BBI isoinhibitors, IBBD2 showed TIA but no detectable CIA, whereas IBB1 267 showed both TIA and CIA (Table 3) . IBBD2 showed a higher specific TIA than IBB1 (3710 ± 268 257 and 2572 ± 122 TIU per mg of protein, respectively, Table 3) in agreement with the nature of 269 the two P 1´ residues. IBB1 showed a high specific CIA (5691 ± 365 CIU per mg of protein), in 270 contrast to IBBD2, where CIA was not detected. These significant differences in specific 271 inhibitory activities are likely to reflect the variation in the amino acid sequences of the inhibitory 272 domains ( Table 3) 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 (Figure 1) (46 ± 2.4 µM) , suggesting a non-304 synergistic effect of individual inhibitors. This was confirmed when the two isoinhibitors were 305 used individually or in combination at a final concentration of 62 µM (data not shown). 306
To investigate whether the effects of soybean BBI on cell growth were due to cell cycle 307 arrest, the cell cycle distribution pattern of HT29 cells was evaluated in the presence or absence of 308 soybean BBI, using different concentrations of BBI (31 and 62 µM). After 24 h exposure to 309 soybean BBI, the accumulation of HT29 cells in the G0-G1 stage was revealed, compared with 310 control cells grown without BBI, and this effect was shown to be dose-dependent (Figure 7) . The 311 histogram of DNA content in HT29 cells treated with 62 µM soybean BBI showed a significant 312 increase in the G0-G1 peak from 62.7 ± 0.2 % to 89.1 ±1.6 %, whereas the cell population in G2-313 M and S stage decreased significantly from 28.2 ± 1.2 % to 4.3 ± 1 % and 9.2 ± 1 % to 6.6 ± 0.6 %, 314 respectively, as compared to untreated cells. 315 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Clemente, A., Vioque, J., Sanchez-Vioque, R., Pedroche, J., Bautista, J., Millán, F., 433 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Database searching was performed using the MASCOT database (http://www.matrixscience.com).
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